Skip to main content
MEDICALSYSTEM BIOTECHNOLOGY CO., LTD logo

MEDICALSYSTEM BIOTECHNOLOGY CO., LTD — Investor Relations & Filings

Ticker · 300439 ISIN · CNE100001Z25 LEI · 3003007XTAWFVR8ASC23 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,715 across all filing types
Latest filing 2025-04-18 Audit Report / Informat…
Country CN China
Listing Shenzhen Stock Exchange 300439

About MEDICALSYSTEM BIOTECHNOLOGY CO., LTD

https://www.nbmksw.com

MedicalSystem Biotechnology Co., Ltd. specializes in the research, development, production, and distribution of in vitro diagnostic (IVD) products. The company offers a comprehensive portfolio that includes biochemical reagents, chemiluminescence immunoassay systems, molecular diagnostic kits, and point-of-care testing (POCT) solutions. Its product line covers a wide range of clinical applications such as liver function, kidney function, blood lipids, and cardiovascular markers. MedicalSystem is recognized for its integrated business model, which combines the manufacturing of high-quality diagnostic instruments with a vast array of compatible reagents. Additionally, the company provides third-party medical laboratory services to healthcare institutions. By focusing on technological innovation and standardized production, MedicalSystem supports clinical laboratories in achieving accurate and efficient diagnostic results for improved patient care.

Recent filings

Filing Released Lang Actions
董事会审计委员会对会计师事务所2024年度履职情况评估及履行监督职责情况的报告
Audit Report / Information Classification · 95% confidence The document is a detailed report from the Board Audit Committee evaluating the performance and supervision of the external audit firm (立信会计师事务所) for the fiscal year 2024. It discusses the audit firm's qualifications, the audit process, communication with management, and the audit committee's oversight activities. It references the 2024 annual audit and related reports but does not contain the full annual report or financial statements itself. The document is a standalone audit-related report focusing on the audit firm's performance and supervisory duties, consistent with an Audit Report / Information filing rather than the full Annual Report (10-K). The document length is under 5,000 characters, but it is substantive and not merely an announcement or certification. Therefore, the appropriate classification is Audit Report / Information (AR). FY 2024
2025-04-18 Chinese
监事会决议公告
Regulatory Filings Classification · 95% confidence The document is a detailed announcement of resolutions passed at the 11th meeting of the 5th Supervisory Board of Meikang Biotechnology Co., Ltd. It includes approvals of the 2024 Supervisory Board Work Report, the 2024 Annual Report and its summary, the 2024 Financial Final Accounts Report, the 2024 Profit Distribution Plan, the 2024 Internal Control Self-Evaluation Report, the 2024 Fundraising Use Report, and other related matters. The document repeatedly states that the detailed reports are published separately on the China Securities Regulatory Commission's designated disclosure website and that these resolutions will be submitted to the 2024 Annual General Meeting for approval. The document itself does not contain the full annual report or financial statements but is a formal announcement of the Supervisory Board's review and approval of these reports and proposals. The document length is 4425 characters, which is relatively short and consistent with an announcement rather than a full report. Therefore, this document is best classified as a Regulatory Filing (RNS) because it is an official announcement of meeting resolutions and references other reports without including them in full.
2025-04-18 Chinese
关于公司2023年限制性股票激励计划首次授予部分第一个解除限售期解除限售条件成就及第一个归属期归属条件成就的公告
Director's Dealing Classification · 95% confidence The document is a detailed announcement from 美康生物科技股份有限公司 regarding the achievement of conditions for the first unlocking period and first vesting period of the company's 2023 restricted stock incentive plan. It includes specifics about the number of shares involved, the list of incentive recipients, approval procedures, legal opinions, and the impact on financials. The content focuses on the status and implementation of a stock incentive plan, including the unlocking and vesting of restricted shares, which is a form of share-based compensation. This type of announcement is related to changes in share ownership by insiders and executives due to stock incentives, which fits the category of Director's Dealing (DIRS) as it reports on personal share transactions by company directors and executives. The document is not a full financial report, audit, or earnings release, nor is it a general regulatory filing or a proxy solicitation. It is a specific announcement about the unlocking and vesting of restricted stock under an incentive plan, which is best classified as Director's Dealing (DIRS). The document length and detail confirm it is not a mere announcement of a report but a substantive disclosure. Therefore, the appropriate classification is DIRS with high confidence.
2025-04-18 Chinese
关于举行2024年度网上业绩说明会及征集相关问题的公告
Investor Presentation Classification · 95% confidence The document is an announcement from 美康生物科技股份有限公司 regarding the scheduling of a 2024 annual performance online briefing (业绩说明会) to be held on April 30, 2025. It references that the 2024 Annual Report has already been reviewed and published on the official disclosure website on April 19, 2025. The document invites investors to participate in the online briefing and submit questions in advance. The document itself does not contain the full annual report or detailed financial data but serves as a notice about the upcoming investor presentation event related to the annual results. Given the short length (1008 characters) and the nature of the content (announcement of an event and reference to the report), this fits the category of an Investor Presentation announcement or a notice about an earnings briefing. However, since it is specifically about an online performance explanation meeting (业绩说明会), which is a form of investor presentation, the best fitting category is Investor Presentation (IP).
2025-04-18 Chinese
公司2025年度董事、监事薪酬（津贴）与考核方案
Remuneration Information Classification · 95% confidence The document is titled as the 2025年度董事、监事薪酬（津贴）与考核方案, which translates to the 2025 Annual Remuneration (Compensation) and Assessment Plan for Directors and Supervisors. It details the principles, management structure, composition, and standards of remuneration for the company's board members and supervisors. The content focuses on compensation policies, performance assessment, and related governance procedures. There is no financial data, audit information, or report publication mentioned. This matches the definition of Remuneration Information filings, which detail compensation for top executives and directors.
2025-04-18 Chinese
2024年度独立董事述职报告（徐玲）
Board/Management Information Classification · 95% confidence The document is titled as the "2024年度独立董事述职报告" which translates to "2024 Annual Independent Director's Work Report." It is a detailed report by an independent director about their duties, attendance at board and committee meetings, communication with auditors, supervision of company governance, and other oversight activities during the year 2024. The content focuses on the independent director's role, governance, and supervisory activities rather than financial results or earnings. It is not an annual report (10-K), audit report (AR), or earnings release (ER). It is also not a proxy statement, voting results, or a regulatory filing. The document is a management-related report focusing on board and governance activities, which fits best under Board/Management Information (MANG). The document length is over 7,000 characters and contains substantive content, not just an announcement or certification. Therefore, the classification is MANG with high confidence.
2025-04-18 Chinese

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.